ADC Buffer Composition for High-Concentration Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) face challenges in formulation stability due to inter-chain disulfide bond oxidation and hydrophobic toxin effects, leading to aggregation and degradation, especially at higher concentrations, which affects their therapeutic efficacy and production efficiency.
Innovation Solution
A pharmaceutical composition comprising an antibody-drug conjugate with specific buffer systems, such as succinate or histidine buffers, along with surfactants like polysorbate 80 and sugars like sucrose, maintains stability by controlling pH and environment, and a lyophilization process stabilizes the formulation for high-concentration use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the concentration of ADC is increased to improve therapeutic efficacy, then the therapeutic effect is enhanced, but aggregation and degradation occur due to inter-chain disulfide bond oxidation and hydrophobic toxin effects
Solution Approach 1:
The patent introduces buffer systems (succinate buffer, histidine buffer) as intermediaries to control the chemical environment and prevent oxidation of inter-chain disulfide bonds. Surfactants (polysorbate 20, polysorbate 80) act as mediators to reduce hydrophobic interactions between toxin molecules, thereby preventing aggregation while maintaining high ADC concentration
Solution Approach 2:
The patent optimizes formulation parameters including pH (adjusted to specific ranges using buffer systems), ionic strength, and surfactant concentration to create an environment that stabilizes ADC at high concentrations. The lyophilization process also changes the physical state from liquid to solid, preserving stability during storage
2Stability of the object's composition
If buffer concentration is increased to maintain pH stability, then pH control is improved, but the complexity of formulation increases
Solution Approach 1:
The patent specifies optimal pH ranges (pH 4.5-6.5 for succinate buffer, pH 5.0-7.0 for histidine buffer) and buffer concentrations (10-50 mM) that provide adequate pH stability without excessive formulation complexity. These parameter optimizations balance stability requirements with formulation simplicity
3Stability of the object's composition
If surfactant concentration is increased to prevent aggregation, then ADC stability is improved, but the cost of formulation increases
Solution Approach 1:
The patent optimizes surfactant concentrations to specific ranges (polysorbate 20: 0.01-1.0 mg/mL, polysorbate 80: 0.01-1.0 mg/mL) that provide adequate protection against aggregation while minimizing formulation cost. This parameter optimization achieves the balance between stability and cost-effectiveness
4Stability of the object's composition
If lyophilization process is applied to stabilize high-concentration ADC, then storage stability is improved, but the manufacturing process complexity increases
Solution Approach 1:
The patent applies lyophilization (freeze-drying) as a preliminary stabilization step before storage. This process removes water from the high-concentration ADC formulation, creating a stable solid state that prevents degradation during long-term storage, thereby enabling high-concentration formulations to maintain stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves enhanced stability and wider therapeutic window, reducing production costs and improving clinical administration, while maintaining the ADC's stability and biological activity.
Implementation Method 1
The buffer of the pharmaceutical composition is succinate buffer or histidine buffer... The pH of the pharmaceutical composition is about 4.5 to about 6.5
Implementation Method 2
a lyophilization process stabilizes the formulation for high-concentration use
Implementation Method 3
along with surfactants like polysorbate 80... reducing production costs and improving clinical administration
Data Source
AI summary
The present disclosure relates to a pharmaceutical composition containing an antibody-drug conjugate and its use. Specifically, the present disclosure relates to a pharmaceutical composition that contains an antibody-drug conjugate in a buffer solution. The pharmaceutical composition involved in the present disclosure exhibits good stability.